Stockreport

PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor

PhaseBio Pharmaceuticals, Inc.  (PHAS) 
Last phasebio pharmaceuticals, inc. earnings: 3/30 08:01 am Check Earnings Report
PDF MALVERN, Pa. and SAN DIEGO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the [Read more]